This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macroscopic, Resectable Stage 3 Melanoma"

263 views
June 14, 2024

Chapters

Neoadjuvant Therapy in Stage III Melanoma

00:00

NADINA Trial: Efficacy & Survival Data

02:16

Toxicity & Quality of Life Assessment

05:19

Comments 0
Login to view comments. Click here to Login